EP3204952B1 - Générateur de radio-isotopes - Google Patents

Générateur de radio-isotopes Download PDF

Info

Publication number
EP3204952B1
EP3204952B1 EP15784292.3A EP15784292A EP3204952B1 EP 3204952 B1 EP3204952 B1 EP 3204952B1 EP 15784292 A EP15784292 A EP 15784292A EP 3204952 B1 EP3204952 B1 EP 3204952B1
Authority
EP
European Patent Office
Prior art keywords
eluent
duct
section
volume
eluate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15784292.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3204952A1 (fr
Inventor
Jérôme PARIS
Thierry DIERICKX
Philippe VANWOLLEGHEM
Valery HOST
Steve DIERICK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National des Radioelements IRE
Original Assignee
Institut National des Radioelements IRE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National des Radioelements IRE filed Critical Institut National des Radioelements IRE
Priority to PL15784292T priority Critical patent/PL3204952T3/pl
Publication of EP3204952A1 publication Critical patent/EP3204952A1/fr
Application granted granted Critical
Publication of EP3204952B1 publication Critical patent/EP3204952B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/0005—Isotope delivery systems

Definitions

  • the present invention relates to a radioisotope generator for medical application, preferably arranged in a shielded form, said formwork being preferably made at least partly of a dense material, such as for example tungsten or lead, comprising a reservoir of eluent and a chromatographic column interconnected by a first eluent transmission conduit, which chromatographic column has a stationary phase charged to a parent radioisotope spontaneously disintegrating to a daughter radioisotope.
  • a radioisotope generator for medical application preferably arranged in a shielded form, said formwork being preferably made at least partly of a dense material, such as for example tungsten or lead, comprising a reservoir of eluent and a chromatographic column interconnected by a first eluent transmission conduit, which chromatographic column has a stationary phase charged to a parent radioisotope spontaneously disintegrating to a daughter radioisotope.
  • This radioisotope generator is used inter alia in the field of nuclear medicine to produce an eluate of radioisotopes (daughter radioisotopes) from a source (i.e. a chromatographic column having a stationary phase charged with maternal radioisotopes which spontaneously disintegrate into daughter radioisotopes which are to be eluted by an eluent).
  • a source i.e. a chromatographic column having a stationary phase charged with maternal radioisotopes which spontaneously disintegrate into daughter radioisotopes which are to be eluted by an eluent.
  • These daughter radioisotopes in the eluate are intended to be used as such or to bind to a molecule, such as for example a biocompatible molecule (protein, antibody, etc.), so as to form a radio-labeled molecule, resulting in the combination of the daughter radioisotope with the molecule, which is generally then administered to a patient by injection, typically in the form of a liquid solution or suspension, when the molecule is biocompatible.
  • a molecule such as for example a biocompatible molecule (protein, antibody, etc.)
  • a radio-labeled molecule resulting in the combination of the daughter radioisotope with the molecule, which is generally then administered to a patient by injection, typically in the form of a liquid solution or suspension, when the molecule is biocompatible.
  • the administration of the radioisotope or radio-labeled molecule in this case allows the diagnosis or the treatment of certain cancers, depending on the choice of the radioisotope and / or the biocompatible molecule.
  • this phenomenon corresponds to an unwanted entrainment by the eluent of maternal radioisotopes which unhook from (or do not cling to) the stationary phase and are found in the eluate at the end of the chromatographic column.
  • parent radioisotope and “parent radioisotopes” mean the radioisotope initially charged on the stationary phase as well as the radioisotopes. intermediate generation that will provide the daughter radioisotope. Indeed, in some cases, the decomposition of the parent radioisotope produces a very short half-life compound which in turn breaks down into the daughter radioisotope of interest.
  • radioisotope (s) mother (s) are called "radioisotope (s) mother (s).
  • radioisotope (s) daughter (s) is intended to mean the radioisotope (s) resulting from the decomposition which will be the eluted radioactive molecule of interest for the uses in nuclear medicine, biomedical research and diagnosis.
  • One solution to reduce this " breakthrough" is to elute the stationary phase of the column with a large volume of eluent and then reconcentrate the eluate resulting from such elution with a reconcentrator to to increase the concentration of daughter radioisotopes and to reduce their activity in maternal radioisotopes to a threshold value which can not be exceeded and for which the toxic effects of this radioisotope can not be declared in the an individual receiving the solution or suspension comprising the radio-labeled biocompatible molecule from the reconcentrated eluate.
  • the reconcentrator In this process, which takes place before the labeling reaction with a biocompatible molecule, the reconcentrator is placed downstream of the generator and connected to the generator at the outlet of the chromatographic column. During reconcentration, the daughter radioisotopes, circulated by a vector solution (typically a physiological saline solution), are retained by a stationary phase which has a specific affinity with these radioisotopes, so that only these are retained. by this stationary phase.
  • a vector solution typically a physiological saline solution
  • This stationary phase is also deliberately chosen so that a small volume of elution is sufficient, for example using physiological saline (of the order of 1.5ml to 5.0ml) and thus allows to have a reconcentrated eluate of restricted volume but wherein the daughter radioisotope activity is sufficiently high and the parent radioisotope activity is sufficiently low to be compatible with the aforementioned medical applications.
  • this reconcentration step is costly, since it requires the establishment of an additional system of reconcentration, and sufficiently long as to observe a significant loss of the yield of activity in daughter radioisotopes in the reconcentrated eluate. thus obtained, which constitutes a loss of profitability of the generator, and an additional risk of contamination.
  • Another solution lies in the fact of producing from the generator a fractional elution well known to those skilled in the art which consists of collecting the eluate in predetermined volume fractions and of retaining and joining the fractions in which, of a on the other hand, the activity in the radioisotope mother is considered sufficiently weak and, on the other hand, the activity in radioisotope is sufficiently important for medical applications.
  • fractional elution has the disadvantage of being a sufficiently long process, since it is necessary, between each fraction, to interrupt the flow of eluate to identify the radio activity. -isotope mother. This results in a significant loss of the yield of activity in daughter radioisotopes in the eluate thus obtained, which is a loss of profitability of the generator and again a risk of contamination. Therefore, fractional elution, to be effective, requires the use of a maintenance system that allows to determine the proper fractionation and to measure in real time the activities in mother and daughter radioisotopes in each fraction, which is an alternative at least as complex as the reconcentration step.
  • the document US 2011/0280770 proposes to meet this need by having a generator comprising an elution line connecting the chromatographic column to the first eluent reservoir (upstream) and the eluate outlet (downstream).
  • This elution line comprises a first sleeve valve arranged to regulate the flow of eluent from the reservoir to the column, and a second sleeve valve placed on a branch of the elution line.
  • This derivation provides a mother radio-isotope loading line ( 62 Zn) concentrated in a liquid phase.
  • the second sleeve valve thus selectively regulates the arrival of 62 Zn radioisotope in the column.
  • a third sleeve valve is present on the elution line, at the eluate outlet, downstream of the chromatographic column. This third line is intended to regulate the flow at the column outlet to a second eluate reservoir.
  • the generator according to the document US 2011/0280770 remainder of complex design since its operation requires continuous control, during the elution of the stationary phase of the column, using pinch valves, on the one hand, of at least two flow rates: the loading rate at 62 Zn from the branch line to the column and the eluent output flow from the eluent tank to the column, and secondly the volumes in solution loaded with radio- isotopes and eluting.
  • the object of the present invention is to provide a radioisotope generator whose design is simplified and which therefore allows easier use, in sterile conditions, than that of the generator described in the document. US 2011/0280770 while avoiding the problem of " breakthrough".
  • this objective is achieved by having a generator as described at the beginning, characterized in that it comprises a second conduit and a valve housed between an upstream portion of the first eluent conduit and a downstream portion of the first eluent conduit, and connecting said second conduit to said upstream portion of the first eluent conduit and the downstream portion of the first eluent conduit, said valve having a first position in which the second conduit is in fluid communication with said first conduit; an upstream portion of the first eluent conduit and a second position wherein the second conduit is in fluid communication with said downstream portion of the first eluent conduit, said second conduit having a bypass portion of a predetermined eluent volume, said section being defined directly between said valve and an end end of a section, said predetermined volume of eluent being a volume sufficient to obtain, when said sufficient volume passes through the chromatographic column, under the action of a driving force of the eluent, an eluate comprising a parent radiois
  • the presence of the second conduit in fluid communication, via the valve, with the first conduit connecting the eluent reservoir to the chromatographic column, provides a generator that is completely sterile when the reservoir, first and second conduits and the valve are previously sterilized before being interconnected to form a closed elution line and connected to the chromatographic column of the generator.
  • first and second conduits and the valve are previously sterilized before being interconnected to form a closed elution line and connected to the chromatographic column of the generator.
  • the various elements mentioned above are interconnected and the resulting elution line is then sterilized as a whole.
  • the generator according to the invention only requires the control of a valve to generate an eluate that is directly usable for medical applications, the volume taken being predetermined by the predetermined length and diameter of the branch section.
  • valve in its first position which is a position in which the second conduit is in fluid communication with said upstream portion of the first eluent conduit so as to load the branch section eluting with a predetermined and sufficient eluent volume.
  • the user positions the valve in its second position in which the second conduit is in fluid communication with said downstream portion of the first eluent conduit, and the eluent is discharged from the branch section to the chromatographic column.
  • the daughter radioisotope which continues to be generated in the column from the parent radioisotope loaded on the column, increases its activity to reach a threshold value of activity which can not to be exceeded and which is governed by a balance between the mother radioisotope and the daughter radioisotope.
  • a cycle is thus formed and it is the frequency between the successive elutions which determines the respective activities in mother and daughter radioisotopes in the eluate obtained for each of these successive elutions.
  • the predetermined volume corresponds here to the sufficient and optimal volume to elute, in the great majority, the daughter radioisotope resulting from the disintegration and a minimal fraction of the mother radioisotope thereby reducing the " breakthrough" phenomenon .
  • the predetermined volume makes it possible, after elution of the column, to obtain an eluate in which a daughter radioisotope activity is measured in a range of values ranging from 60.0% to 100.0%, preferably from 70.0% to 100.0%, more particularly greater than 80.0% with respect to the daughter radioisotope activity present on the column at the time of elution, while the radioisotope activity
  • the mother in the eluate is in the range of 0.0% to 30.0% relative to the daughter radioisotope activity of said eluate.
  • the generator according to the present invention therefore makes it possible, for each elution with a sufficient predetermined eluent volume, to obtain a completely surprising daughter eluting profile of the daughter radioisotope.
  • the elution profile of the daughter radioisotope traditionally has a first fraction comprising mainly the radioisotope mother preceding a second fraction comprising the daughter radioisotope in majority.
  • the generator according to the present invention for an elution with the sufficient predetermined volume of eluent, it is ensured and, moreover, under sterile conditions, not only the control of the activity of parent radioisotopes in the eluate, but also an activity in sufficient daughter radioisotopes, so as to obtain an eluate which is directly exploitable in the framework of medical applications.
  • the eluate obtained by the passage of the predetermined volume of eluent in the chromatographic column of the generator according to the invention has a peak elution of the daughter radioisotope narrow and substantially free of parent radioisotopes by optimizing the the synchronization between the elution and the complete generation of daughter radioisotopes on the stationary phase according to the secular cycle of disintegration of the parent radioisotopes.
  • the daughter isotope solutions of interest are recovered by a succession of loading and unloading of the section alternately, until the eluent contained in the reservoir is exhausted: it is therefore discontinuous elution which consists of a succession of elutions with the sufficient volume of eluent.
  • each elution is associated with the collection of an eluate volume for an appropriate medical use.
  • the user will take care to dry the column, for example by pumping sterilized ambient air from the end end of the section or from a free end of the second conduit to the eluate outlet.
  • the drying makes it possible to evacuate a residual volume of excess eluent present in the column, and thus to minimize the risk of migrating the parent radioisotope towards the eluate outlet of the column between two successive elutions.
  • the choice of sufficient predetermined volume is determined by the elution profile of the radioisotopes and therefore: (i) by the physicochemical properties of the chromatographic column and the eluent; (ii) as well as by the couple of radioisotopes mothers and daughters employed.
  • the generator according to the invention therefore constitutes a simpler alternative design and use to the solutions proposed in the state of the art, and in particular to the solution provided by conventional dry generators for which it is necessary to systematically manually load the column by injection of a predetermined volume of eluent, this type of generator not comprising by definition no eluent reservoir.
  • said reservoir is situated above said chromatographic column, said end-of-section end, which may be a free end of the second conduit, being disposed at a sufficient height, measured from an apical end of the column chromatographic, so that the gravitational force has sufficient intensity to allow a flow of the eluent through the sampling section.
  • At least one branch section portion connected to said valve is inclined with respect to a horizontal plane of an angle ⁇ defined between said horizontal plane and a line intersecting said horizontal plane, said angle ⁇ having a predetermined value of so that its sine value is greater than 0 and less than or equal to 1 and its cosine value is between -1 and 1.
  • the intensity of the gravitational force acting on the eluent withdrawn to the sampling section is first determined by the height of the fall, measured from the apical end of the chromatographic column, from the stretch. of derivation to the chromatographic column, and additionally, by the angle ⁇ whose value determines the inclination of the section portion connected to said valve.
  • the inclination thus allows a gravitational flow of the predetermined sufficient volume of eluent.
  • the generator according to the invention comprises a means for blocking the eluent in fluid communication with said branch section, so as to block the passage of said eluent volume beyond said end of section end.
  • the presence of the blocking means makes it possible, on the one hand, to accurately determine the sampled volume and, on the other hand, possibly to avoid the overflow of said eluent volume by said free end of the second duct.
  • said free end is connected to a second sterile filter of inverse polarity to that of said eluent.
  • Said end-of-section end may also be directly connected to a first sterile filter of inverse polarity to that of said eluent, said first sterile filter being said means for blocking the eluent.
  • the generator according to the invention comprises a pumping means arranged to be connected hermetically to an eluate outlet and intended to pump, when said valve is in its second position and after elution of the stationary phase of the column. chromatographic by said sufficient volume of eluent, a fluid from the end end of the section or from the free end of the second conduit to the eluate outlet, said fluid being a remaining fraction of said sufficient volume of eluent present in the column or ambient air pumped from said free end or said stub end of said second conduit.
  • the pumping means may be a vacuum vessel or an actuator comprising a piston mounted in a cylinder, which cylinder has a first end communicating with said eluate outlet of the chromatographic column, said piston being extended by an arm extending out of said cylinder through an orifice on a second cylinder end, opposite to the first cylinder end, which piston has a first rest position and a fluid pumping position, which piston, when it is set in motion between said first rest position and said pumping position, generates a pumping force of the fluid.
  • the pumping means allows, after each elution, to evacuate the excess eluent present in the column and possibly dry the latter so as to obtain a column which is dried or slightly impregnated by elution.
  • the method comprises a step of blocking the eluent, subsequent to said injection step, so as to block the passage of said eluent volume beyond said end end of the section.
  • the method may further comprise a purge step, carried out before the drying step, when the valve is in its second position and after elution of the stationary phase of the chromatographic column by the sufficient volume of eluent, which consists of a pumping a remaining fraction of the sufficient volume of eluent present in the column.
  • the parent radioisotope activity is in a range of values ranging from 0.0% to 20%, advantageously from 0.0% to 10%, more preferably from 0.0% to 5%, 0%, still more preferably 0.0% to 2.0%, more preferably 0.0% to 1.0%, based on the daughter radioisotope activity of said eluate.
  • the parent radioisotope activity is equal to 0.0 mCi.
  • the figure 1 schematically illustrates a first embodiment of the generator according to the invention.
  • FIGS. 2a and 2b illustrate schematically two possible variants of a second embodiment of the generator according to the invention.
  • the figure 3 schematically illustrates a third embodiment of the generator according to the invention.
  • the radioisotope generator 1 according to the invention shown in FIG. figure 1 comprises a reservoir 2 of eluent and a chromatographic column 3 interconnected by a first eluent transmission conduit 4, so that the eluent contained in the reservoir 2 is in fluid communication with the chromatographic column 3.
  • the chromatographic column 3 comprises a stationary phase impregnated with elution and loaded with a parent radioisotope spontaneously disintegrating into a daughter radioisotope.
  • the first eluent transmission conduit 4 connects an eluent inlet 5 disposed upstream of the stationary phase to an eluent outlet 6 of the reservoir 2.
  • the radioisotope generator 1 further comprises a second duct 7 and a valve 8 connecting an upstream portion 4 'of the first eluent duct and a downstream portion 4 "of the first eluent duct.
  • eluent outlet 6 of the tank 2 at a first inlet 8 'of the valve 8 while the downstream part 4 "connects a second inlet 8" of the valve 8 to the eluent inlet 5 of the chromatographic column 3.
  • the valve 8 further connects an end 7 'of bonded portion of the second conduit 7 to the upstream portion 4' and downstream 4 "of the first conduit 4 eluent.
  • the second duct 7 is in fluid connection with the valve 8 via a connection between the end 7 'of the bonded portion of the second duct 7 and a third inlet 8' "of the valve 8.
  • valve 8 has a first position in which the second duct 7 is in fluid communication with the upstream portion 4 'of the first eluent duct 4 and a second position in which the second duct 7 is in fluid communication with the duct 4. downstream part 4 "of the first eluent line 4.
  • the second conduit 7 further has a branch section 9 of a predetermined volume v of eluent. This section 9 is defined directly between the valve 8 and an end 9 'end section.
  • the predetermined volume of eluent v is defined by a run-length branch and a diameter of the branch section.
  • the section 9 is defined between the end 7 'of the bonded portion of the second conduit 7 and the end 9' end of the section.
  • the end-of-section end is connected to an eluent locking means 17 in fluid communication with the bypass section 9, so as to block the passage of the eluent volume beyond the end 9 'of the eluent. end of section.
  • the blocking means 17 is a sterile filter of inverse polarity to that of the eluent whose function is to let the ambient air pass through the bypass section 9 and to block the passage of the eluent in a defined direction since the end 7 'of the bonded portion of the second conduit 7 to the end 9' end of the section.
  • the generator 1 is disposed in a shielded casing C for example made at least partly of a dense material, such as for example tungsten or lead.
  • the formwork C comprises a first access opening 10 to the reservoir 2 and an outlet opening 11 disposed downstream of an eluate outlet 12 of the chromatographic column 3 and arranged to be traversed by a third conduit 12 'of exit eluate arranged to connect the eluate outlet 12 of the column 3 to an eluate container 13 arranged to be disposed in a chamber 14 formed in the formwork and disposed downstream of the outlet opening 11.
  • the eluate container 13 and / or the chamber 14 comprises a shielding of a dense material, such as for example tungsten or lead.
  • the reservoir 1 is disposed above the chromatographic column 3.
  • At least a portion of the branch portion 9 connected to the valve 8 is inclined relative to a horizontal plane h of an angle ⁇ defined between the horizontal plane h and a line d intersecting the horizontal plane h.
  • the angle ⁇ has a predetermined value so that its sine value is greater than 0 and less than or equal to 1 and its cosine value is between -1 and 1.
  • valve 8 is first disposed in its first position.
  • the eluent flows from the reservoir 2 through the upstream portion 4 'of the first conduit 4 to the second conduit 7.
  • the branch section 9 is filled, under the effect of the gravitational force acting on a volume V of eluent contained in the tank 2, of the predetermined volume v of eluent according to a bypass flow at a value predetermined by the length and the diameter of branch section 9.
  • the air contained in the section is driven to the sterile filter 17 by the eluent.
  • the eluent run from the reservoir to the free end 15 is stopped by the presence of the sterile filter 17.
  • the valve is then placed in its second position.
  • the eluent flows from the sample section 9 through the chromatographic column 3 according to an elution rate determined by the pressure drop of the chromatographic column 3.
  • the predetermined volume v of eluent is a sufficient volume V s to obtain, when the sufficient volume passes under the action of a driving force of the eluent, which can be for example a force of withdrawal of the eluent generated by a pump system connected to the output of the chromatographic column 3 at the determined elution rate, an eluate comprising a radioisotope activity in a range of values ranging from 0.0% to 30.0% with respect to an activity in daughter radioisotopes of said eluate.
  • a driving force of the eluent which can be for example a force of withdrawal of the eluent generated by a pump system connected to the output of the chromatographic column 3 at the determined elution rate
  • the parent radioisotope activity in the eluate is preferably in a range of from 0.0% to 20.0%, more preferably 0.0% to 10.0% relative to the activity in daughter radioisotopes of said eluate.
  • the parent radioisotope activity is in a range of values ranging from 0.0% to 5.0% with respect to the activity of daughter radioisotopes of said eluate.
  • the parent radioisotope activity is in a range from 0.0% to 2.0% relative to the daughter radioisotope activity of said eluate.
  • the parent radioisotope activity is in a range of values ranging from 0.0% to 1.0% relative to the daughter radioisotope activity of said eluate.
  • the activity of the parent radioisotope is preferably equal to 0.0 mCi.
  • FIGS. 2a and 2b illustrate a portion of two distinct variants of a second embodiment of the generator 1 according to the invention.
  • the second embodiment incorporates the features of the first embodiment and, additionally, a pumping means M P arranged to be connected from hermetically at the eluate outlet 12.
  • the pumping means M P can be for example a vacuum container.
  • the pumping means M P may be an actuator 18 comprising a piston 19 mounted in a cylinder 20 ( figure 2a ).
  • the cylinder 20 has a first end 21 communicating with the outlet 12 of the eluate of the chromatographic column 3.
  • the piston 19 is extended by an arm 22 which extends out of the cylinder 20 through an orifice 23 present on a second end 24 of the cylinder, opposite the first end of the cylinder 21.
  • the piston has a first rest position R and a pumping position P (see FIG. figure 2b by equivalence).
  • the first valve 8 In operation, after a first elution and before a second elution following, the first valve 8 is maintained in its second elution position and the pumping means M P is connected hermetically to the eluate outlet 12 while s' ensuring that the valve 8 is positioned in its second position.
  • the eluate outlet is extended by a needle which is connected to a vacuum capsule by drilling a sealed wall covering a fluid inlet opening on the capsule.
  • the suction of the free eluent and the passage of air in the column thus serves to purge and dry the latter so as to obtain, between two elution, a column which is dried or weakly impregnated by elution.
  • the capsule After purging and drying the column, the capsule is disconnected from the eluate outlet 12 and the eluate container 13 is connected back to the column.
  • the container comprises a sealed wall intended to be traversed by the needle disposed in the extension of the eluate outlet 12 of the column 3.
  • a new elution is then performed by first positioning the first valve 8 in its first position to load the bypass section 9 by eluting and then positioning the first valve 8 in its second elution position. This new elution is then followed by a new purging and drying step.
  • the daughter radioisotope which continues to be generated in the column from the parent radioisotope loaded on the column, increases in activity to reach a threshold value. an activity that can not be surpassed and governed by a secular equilibrium between the mother radioisotope and the daughter radioisotope.
  • a cycle is thus formed and it is the frequency between each successive elution (second, third, etc. elution) at the first elution which determines the respective activities in mother and daughter radioisotopes in the eluate obtained for each of these elutions. successive.
  • the actuator 18 can be hermetically connected by a second valve 25 to the eluate outlet 12 ( figure 2b ).
  • the second valve 25 has an elution position in which the third conduit 12 'is in fluid communication with the eluate container 13 via a fourth conduit 12 "connecting the eluate container 13 to the valve, and a purge position in which the third conduit 12 'is in fluid communication with the pumping means.
  • the second valve 25 In operation, after a first elution and before a second elution following, the second valve 25, initially in its elution position is disposed in its purge position, while the first valve 8 is maintained in its second elution position. The piston is then moved between its first rest position R and its second pumping position P, which generates a pumping force of the remaining fraction of the sufficient volume of eluent.
  • the remaining fraction of the sufficient volume of eluent is therefore conveyed from the chromatographic column 3 to the cylinder 20 of the actuator 18 which fills with eluent.
  • the second valve 25 is disposed in its first position and a new elution is achieved by first positioning the first valve 8 in its first position to load the branch section 9 eluting and then positioning the first valve 8 in its second elution position.
  • the generator according to a third embodiment ( figure 3 ) further comprises a pressure switch 15 'connected to the free end 15 of the second duct or to the end end 9' of section 9.
  • the pressure switch 15 makes it possible to monitor the elution rate of the sufficient volume of eluent, just like a purge flow rate, that is to say a pumping rate of the eluent, and a drying rate, that is to say a rate of pumping air through the column, and to determine any operating anomalies of the generator.
  • the choice of sufficient predetermined volume is determined by the elution profile of the radioisotopes and therefore: (i) by the physico-chemical properties of the chromatographic column and the eluent; (ii) as well as by the couple of radioisotopes mothers and daughters employed.
  • the present invention also relates to a method of eluting a chromatographic column 3 of a radioisotope generator 1 comprising a reservoir 2 of eluent and connected to a chromatographic column 3 by a first eluent line 4, which chromatographic column 3 has a stationary phase impregnated eluting and charged to a mother radioisotope spontaneously disintegrating to a daughter radioisotope.
  • the method further comprises a step of drying the column by pumping ambient air from the end end 9 'of section 9 or from a free end 15 of the second conduit 17 to the eluate outlet 12, and further the method comprises a step of blocking the eluent, subsequent to said injection step, so as to block the passage of said eluent volume beyond said end end of section 9 '.
  • the ambient air is sterilized by passing through the sterile filter 17 present on the second duct 7.
  • a purge step can be performed before the drying step. This purge step is performed when the valve 8 is in its second position and after elution of the stationary phase of the chromatographic column 3 by the sufficient volume of eluent, which consists of pumping a remaining fraction of the sufficient volume of eluent present in column 3.
  • the predetermined volume of eluent is a volume sufficient to obtain, when the sufficient volume passes through the chromatographic column 3, an eluate comprising a parent radioisotope activity in a range of values from 0.0% to 30.0% relative to activity in daughter radioisotopes of the eluate.
  • the method comprises a step of blocking the eluent, subsequent to said injection step, so as to block the passage of said eluent volume beyond said end end of section 9 '.
  • the blocking step is ensured by the presence of a sterile filter 17 of inverse polarity to that of the eluent whose function is to let the air pass through the bypass section 9 and block the passage of the eluent. in a sen defined from the end 7 'of the bonded portion of the second conduit 7 to the end 9' end of the section.
  • the process according to the invention makes it possible, preferably, to obtain a parent radioisotope activity in a range of values ranging from 0.0% to 20% relative to the activity of daughter radioisotopes of said eluate.
  • the parent radioisotope activity is in a range of values ranging from 0.0% to 10% relative to the activity of daughter radioisotopes of said eluate.
  • the parent radioisotope activity is in a range of values ranging from 0.0% to 5.0% with respect to the activity of daughter radioisotopes of said eluate.
  • the parent radioisotope activity is in a range from 0.0% to 2.0% relative to the daughter radioisotope activity of said eluate.
  • the parent radioisotope activity is within a range of 0.0% to 1.0% based on the daughter radioisotope activity of said eluate.
  • the parent radioisotope activity is equal to 0.0 mCi.
  • Test 1 relates to the 99 Mo / 99m Tc pair (mother / daughter) on a first titanium-based stationary phase of a first generator according to the invention made in aqueous phase at acidic pH.
  • the activity loaded on the stationary phase was 27.9 mCi at the loading time T 0 .
  • Test 2 relates to the torque 99 Mo / 99m Tc on a second stationary phase based on aluminum of a second generator according to the invention made in aqueous phase at acidic pH.
  • the activity loaded on the stationary phase was 57.8 mCi at the loading time T 0 .
  • the reservoir consists of a bag of NaCl saline solution concentrated to 0.9% by volume.
  • the two generators were eluted daily for a fixed period in order to follow the elution yields and release rates in 99 MB in each of the eluates taken daily (" breakthrough ").
  • 99mTc sodium pertechnetate
  • the activity in maternal radio-istopes detected in the eluate is on average less than a factor of 10 -6 - 10 -8 relative to the activity in radioisotopes daughter in the same eluate, which means a parent radioisotope activity of less than 1.0% with respect to the daughter radioisotope activity of the eluate, which is quite remarkable.
  • the generator according to the present invention may be used in other applications than those that are part of a use for pharmaceutical or medical purposes.
  • a generator comprising a valve
  • the present invention is not limited to a generator comprising only one valve but also covers other embodiments in which several valves connect fluidically the collection section to the tank and to the column.
  • a fourth embodiment in which the generator comprises a first valve connecting the sampling section to the reservoir and a second valve connecting the same section to the chromatographic column can quite well be considered as an equivalent implementation of the generator. according to the invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Nuclear Medicine (AREA)
EP15784292.3A 2014-10-07 2015-10-06 Générateur de radio-isotopes Active EP3204952B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL15784292T PL3204952T3 (pl) 2014-10-07 2015-10-06 Generator izotopów promieniotwórczych

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2014/0745A BE1022468B1 (fr) 2014-10-07 2014-10-07 Generateur de radio-isotopes
PCT/EP2015/072971 WO2016055429A1 (fr) 2014-10-07 2015-10-06 Générateur de radio-isotopes

Publications (2)

Publication Number Publication Date
EP3204952A1 EP3204952A1 (fr) 2017-08-16
EP3204952B1 true EP3204952B1 (fr) 2018-09-05

Family

ID=52648759

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15784292.3A Active EP3204952B1 (fr) 2014-10-07 2015-10-06 Générateur de radio-isotopes

Country Status (11)

Country Link
US (1) US10186338B2 (pl)
EP (1) EP3204952B1 (pl)
AU (1) AU2015330084B2 (pl)
BE (1) BE1022468B1 (pl)
BR (1) BR112017006753B1 (pl)
CA (1) CA2963311C (pl)
DK (1) DK3204952T3 (pl)
ES (1) ES2696355T3 (pl)
PL (1) PL3204952T3 (pl)
TW (1) TW201626401A (pl)
WO (1) WO2016055429A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1022468B1 (fr) * 2014-10-07 2016-04-13 Institut National Des Radioéléments Generateur de radio-isotopes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585009A (en) * 1983-02-28 1986-04-29 E. R. Squibb & Sons, Inc. Strontium-rubidium infusion pump with in-line dosimetry
JP4495453B2 (ja) * 2001-06-22 2010-07-07 ピージー リサーチ ファンデーション，インコーポレーテッド 自動放射性核種分離システム
EP2911758B1 (en) * 2012-10-25 2018-01-10 Cyclopharm Ltd. A radioisotope concentrator
BE1022468B1 (fr) * 2014-10-07 2016-04-13 Institut National Des Radioéléments Generateur de radio-isotopes

Also Published As

Publication number Publication date
CA2963311A1 (fr) 2016-04-14
PL3204952T3 (pl) 2019-07-31
BR112017006753B1 (pt) 2022-11-29
CA2963311C (fr) 2023-01-24
DK3204952T3 (en) 2018-12-03
US20170294246A1 (en) 2017-10-12
BR112017006753A2 (pt) 2018-04-10
ES2696355T3 (es) 2019-01-15
BE1022468B1 (fr) 2016-04-13
WO2016055429A1 (fr) 2016-04-14
EP3204952A1 (fr) 2017-08-16
US10186338B2 (en) 2019-01-22
AU2015330084A1 (en) 2017-04-20
TW201626401A (zh) 2016-07-16
AU2015330084B2 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
Bauwens et al. Optimal buffer choice of the radiosynthesis of 68Ga–Dotatoc for clinical application
CN110740757B (zh) 新型psma-结合剂及其用途
KR102000867B1 (ko) 항-cgrp 항체 제제
Decristoforo et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides
EP3204952B1 (fr) Générateur de radio-isotopes
Petrik et al. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system
Deng et al. Dextran-mimetic quantum dots for multimodal macrophage imaging in vivo, ex vivo, and in situ
Arulsudar et al. Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine
US20230414796A1 (en) Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
US7390411B2 (en) Method for preparing a compound of interaction of active substances with a porous support using supercritical fluid
Gustafson et al. Blood triggered rapid release porous nanocapsules
JP5469794B2 (ja) 放射線標識されたＣｕ−ビス（チオセミカルバゾン）錯体を容易に調合して、医療現場における６２Ｃｕキット製剤の高濃度輸送をするための小型６２Ｚｎ／６２Ｃｕ生成装置
Saunier et al. Investigating the static or dynamic flexural and compressive stresses on flexible tubing: Comparison of clamp and peristaltic pump impact on surface damages and particles leaching during infusion acts
EP3204951B1 (fr) Générateur de radio-isotopes à phase stationnaire comprenant de l'oxyde de titane
WO2002069959A1 (fr) Dispositif de conditionnement d'une solution d'oxaliplatine
Patil et al. Enhancing dissolution rate of ziprasidone via co-grinding technique with highly hydrophilic carriers
CN108066286A (zh) 炔丙基半胱氨酸纳米粒长循环脂质体及其制备方法和用途
Szegvári et al. Tracking of enantioselective solubility of rac‐norgestrel in the presence of cyclodextrin by a CD spectroscopic method
FR3060303A1 (fr) Poche a usage medical comportant trois compartiments
CN104144742B (zh) 用于固体蛋白质组合物的快速溶解的方法和装置
CA3119196A1 (fr) Procede de transfert d'un radioisotope entre deux phases stationnaires contenues dans deux colonnes de chromatographie
JPH06321812A (ja) 放射性ヨウ素標識脂肪酸−シクロデキストリン複合体およびこれを含有するイメージング剤
EP3863686A1 (en) Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
EP4284771A1 (fr) Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués
JP2021527682A (ja) 放射性医薬品用のソマトスタチンアナログを含む組成物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: DIERICK, STEVE

Inventor name: VANWOLLEGHEM, PHILIPPE

Inventor name: HOST, VALERY

Inventor name: PARIS, JEROME

Inventor name: DIERICKX, THIERRY

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180319

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VANWOLLEGHEM, PHILIPPE

Inventor name: DIERICKX, THIERRY

Inventor name: HOST, VALERY

Inventor name: PARIS, JEROME

Inventor name: DIERICK, STEVE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1239944

Country of ref document: HK

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1038803

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015015839

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 4

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: GEVERS SA, CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20181126

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2696355

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190115

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181205

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 29302

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180403591

Country of ref document: GR

Effective date: 20190404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190105

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190105

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015015839

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD SA NEUCHATEL CONSEILS EN PROPRIETE INTE, CH

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

26N No opposition filed

Effective date: 20190606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151006

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180905

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180905

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1038803

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180905

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230918

Year of fee payment: 9

Ref country code: NL

Payment date: 20230913

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230918

Year of fee payment: 9

Ref country code: PL

Payment date: 20230915

Year of fee payment: 9

Ref country code: FR

Payment date: 20230913

Year of fee payment: 9

Ref country code: BE

Payment date: 20230913

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20231026

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231024

Year of fee payment: 9

Ref country code: GR

Payment date: 20231018

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231110

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231023

Year of fee payment: 9

Ref country code: NO

Payment date: 20231018

Year of fee payment: 9

Ref country code: IT

Payment date: 20231024

Year of fee payment: 9

Ref country code: IE

Payment date: 20231018

Year of fee payment: 9

Ref country code: FI

Payment date: 20231026

Year of fee payment: 9

Ref country code: DK

Payment date: 20231023

Year of fee payment: 9

Ref country code: DE

Payment date: 20231027

Year of fee payment: 9

Ref country code: CZ

Payment date: 20231004

Year of fee payment: 9

Ref country code: CH

Payment date: 20231102

Year of fee payment: 9

Ref country code: AT

Payment date: 20231018

Year of fee payment: 9